Since the discovery of the RUNX1-RUNX1T1 fusion protein, numerous studies have revealed that t(8;21) AML is a highly heterogeneous disease from a biological and a clinical point of view2. This evidence concerns the gene RUNX1 and acute myeloid leukemia.